Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

MLA

Krämer, Alwin, et al. “Molecularly Guided Therapy versus Chemotherapy after Disease Control in Unfavourable Cancer of Unknown Primary (CUPISCO): An Open-Label, Randomised, Phase 2 Study.” The Lancet, vol. 404, no. 10452, Aug. 2024, pp. 527–39. EBSCOhost, https://doi.org/10.1016/S0140-6736(24)00814-6.

APA

Krämer, A., Bochtler, T., Pauli, C., Shiu, K.-K., Cook, N., de Menezes, J. J., Pazo-Cid, R. A., Losa, F., Robbrecht, D. G., Tomášek, J., Arslan, C., Özgüroğlu, M., Stahl, M., Bigot, F., Kim, S. Y., Naito, Y., Italiano, A., Chalabi, N., Durán-Pacheco, G., … Mileshkin, L. (2024). Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. The Lancet, 404(10452), 527–539. https://doi.org/10.1016/S0140-6736(24)00814-6

Chicago

Krämer, Alwin, Tilmann Bochtler, Chantal Pauli, Kai-Keen Shiu, Natalie Cook, Juliana Janoski de Menezes, Roberto A Pazo-Cid, et al. 2024. “Molecularly Guided Therapy versus Chemotherapy after Disease Control in Unfavourable Cancer of Unknown Primary (CUPISCO): An Open-Label, Randomised, Phase 2 Study.” The Lancet 404 (10452): 527–39. doi:10.1016/S0140-6736(24)00814-6.